Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble fas ligand

American Journal of Pathology

Volumn 162, Issue 5, 2003, Pages 1515-1520

  Abe, Riichiro ^a   Shimizu, Tadamichi ^b   Shibaki, Akihiko ^b   Nakamura, Hideki ^b   Watanabe, Hirokazu ^b   Shimizu, Hiroshi ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FAS LIGAND;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATINOCYTE; MALE; MONONUCLEAR CELL; NICK END LABELING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 0037407710     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64284-8     Document Type: Article

References (26)

1. Becker DS: Toxic epidermal necrolysis. Lancet 1998, 351:1417-1420
2. Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994, 102:28-30
3. Wolkenstein PC, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996, 134:710-714
4. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA: Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993, 129:466-468
5. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M: Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995, 131:544-551
6. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493
7. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365
8. Sayama K, Yonehara S, Watanabe Y, Miki Y: Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 1994, 103:330-334
9. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N: Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994, 84:1201-1208
10. Wehrli P, Viard I, Bullani R, Tschopp J, French LE: Death receptors in cutaneous biology and disease. J Invest Dermatol 2000, 115:141-148
11. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995, 182:1777-1783
12. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995, 14:1129-1135
13. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 1996, 2:317-322
14. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993, 129:92-96
15. Gavrieli Y, Sherman Y, BenSasson SA: Identification of programmed cell death by in situ specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501
16. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA: T cell-mediated Fas induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000, 106:25-35
17. Lerner LH, Qureshi AA, Reddy BV, Lerner EA: Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000, 114:196-199
18. Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002, 118:728-733
19. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998, 352: 1586-1589
20. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285
21. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E: Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996, 9:769-773
22. Sherertz EF, Jegasothy BV, Lazarus GS: Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy." J Am Acad Dermatol 1985, 12:178-181
23. Halebian PH, Corder VJ, Madden MR, Finklestein JL Shires GT: Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986, 204:503-512
24. Kelemen JJ, Cioffi WG, McManus WF, Mason AD Pruitt BA: Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995, 180:273-278
25. Hewitt J, Ormerod AD: Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol 1992, 17:264-265
26. Fischer M, Fiedler E, Marsch WC, Wohlrab J: Antitumour necrosis factor-antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002, 146:707-708